Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariola Fotin-Mleczek

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Chembiochem : a European Journal of Chemical Biology|October 29, 2005
Break on through to the other side-biophysics and cell biology shed light on cell-penetrating peptidesRainer Fischer, Mariola Fotin-Mleczek, Hansjörg Hufnagel, et al.
The Journal of Biological Chemistry|January 7, 2004
A stepwise dissection of the intracellular fate of cationic cell-penetrating peptidesRainer Fischer, Karsten Köhler, Mariola Fotin-Mleczek, et al.
RNA Biology|October 16, 2012
Developing mRNA-vaccine technologiesThomas Schlake, Andreas Thess, Mariola Fotin-Mleczek, et al.
Traffic (Copenhagen, Denmark)|June 26, 2007
A comprehensive model for the cellular uptake of cationic cell-penetrating peptidesFalk Duchardt, Mariola Fotin-Mleczek, Heinz Schwarz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 20, 2019
mRNA: A Novel Avenue to Antibody Therapy?Thomas Schlake, Moritz Thran, Katja Fiedler, et al.
Chembiochem : a European Journal of Chemical Biology|July 28, 2006
A targeted protease substrate for a quantitative determination of protease activities in the endolysosomal pathwayRainer Fischer, Daniel Bächle, Mariola Fotin-Mleczek, et al.
The Journal of Biological Chemistry|July 10, 2002
Endogenous membrane tumor necrosis factor (TNF) is a potent amplifier of TNF receptor 1-mediated apoptosisMonika Weingärtner, Daniela Siegmund, Ulrich Schlecht, et al.
NPJ Vaccines|April 17, 2021
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodentsSusanne Rauch, Nicole Roth, Kim Schwendt, et al.
Vaccine|June 9, 2016
Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunityAleksandra Kowalczyk, Fatma Doener, Kai Zanzinger, et al.
Radiation Oncology (London, England)|August 17, 2014
mRNA-based vaccines synergize with radiation therapy to eradicate established tumorsMariola Fotin-Mleczek, Kai Zanzinger, Regina Heidenreich, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Chembiochem : a European Journal of Chemical Biology|October 29, 2005
Break on through to the other side-biophysics and cell biology shed light on cell-penetrating peptidesRainer Fischer, Mariola Fotin-Mleczek, Hansjörg Hufnagel, et al.
The Journal of Biological Chemistry|January 7, 2004
A stepwise dissection of the intracellular fate of cationic cell-penetrating peptidesRainer Fischer, Karsten Köhler, Mariola Fotin-Mleczek, et al.
RNA Biology|October 16, 2012
Developing mRNA-vaccine technologiesThomas Schlake, Andreas Thess, Mariola Fotin-Mleczek, et al.
Traffic (Copenhagen, Denmark)|June 26, 2007
A comprehensive model for the cellular uptake of cationic cell-penetrating peptidesFalk Duchardt, Mariola Fotin-Mleczek, Heinz Schwarz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 20, 2019
mRNA: A Novel Avenue to Antibody Therapy?Thomas Schlake, Moritz Thran, Katja Fiedler, et al.
Chembiochem : a European Journal of Chemical Biology|July 28, 2006
A targeted protease substrate for a quantitative determination of protease activities in the endolysosomal pathwayRainer Fischer, Daniel Bächle, Mariola Fotin-Mleczek, et al.
The Journal of Biological Chemistry|July 10, 2002
Endogenous membrane tumor necrosis factor (TNF) is a potent amplifier of TNF receptor 1-mediated apoptosisMonika Weingärtner, Daniela Siegmund, Ulrich Schlecht, et al.
NPJ Vaccines|April 17, 2021
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodentsSusanne Rauch, Nicole Roth, Kim Schwendt, et al.
Vaccine|June 9, 2016
Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunityAleksandra Kowalczyk, Fatma Doener, Kai Zanzinger, et al.
Radiation Oncology (London, England)|August 17, 2014
mRNA-based vaccines synergize with radiation therapy to eradicate established tumorsMariola Fotin-Mleczek, Kai Zanzinger, Regina Heidenreich, et al.
Pageof 4